#Ireland #Dublin #Peyronie's Disease #XIAFLEX #Keenova

Keenova Reaches a Milestone in Peyronie's Disease Treatment

Keenova Therapeutics plc recently announced a remarkable achievement: over 100,000 men have been prescribed XIAFLEX® (collagenase clostridium histolyticum) for the treatment of Peyronie's disease (PD). This FDA-approved, non-surgical treatment has become a pivotal option for adult men experiencing this often-stigmatized condition, characterized by a curvature of the penis due to fibrous scar tissue.

Understanding Peyronie's Disease

Peyronie's disease affects male sexual health and can lead to significant emotional and physical distress. The condition typically presents with a curvature greater than 30 degrees, making intimacy challenging and uncomfortable. Despite its prevalence, diagnosis rates remain low, largely because many men feel uncomfortable discussing their symptoms or seeking help. This has led to a significant population of untreated individuals who are unaware of their options.

According to Dan Plunkett, Executive Director of Marketing at Keenova, reaching this milestone demonstrates the courage of patients who have chosen to seek help for their condition. He emphasized that the commitment to supporting men's health and providing effective treatments remains a top priority for Keenova.

The Impact of XIAFLEX

Launched in 2013, XIAFLEX has changed the landscape for managing Peyronie's disease. With its ability to help men regain control over their health and intimacy, it offers hope to those who previously had limited options. However, even with this significant progress, the journey doesn’t end here. Keenova aims to enhance awareness and education around Peyronie's disease to encourage more men to speak up and seek medical advice.

In its 2026 initiatives, Keenova plans to bolster marketing efforts aimed at both men and their partners. By launching campaigns across digital, social media, and streaming platforms like Prime Video, CBS, HBO Max, Hulu, and Peacock, the company seeks to ignite conversations surrounding the condition. Notably, initiatives like Bent Carrot and Prime Time aim to engage not just patients but their partners, creating an inclusive dialogue.

Enhancing Patient Engagement

Social media has become an essential tool for education and empowerment. Keenova intends to expand its outreach on platforms like Meta and Reddit, where user-generated content can foster connection and encourage men living with PD to share their experiences. These patient stories can demystify the condition, reducing stigma and making it easier for others to come forward.

Additionally, technological advancements are supporting medical professionals. In 2025, Keenova launched the Spatial Computing Injection Simulator, allowing urology specialists to blend digital simulation and physical models to improve injection techniques for XIAFLEX. Keenova plans to increase access to this tool, further enhancing the confidence of healthcare providers in treating Peyronie's disease.

Moving Forward

Looking ahead, Keenova's commitment to improving the quality of life for men with Peyronie's disease remains unwavering. By raising awareness, enhancing marketing initiatives, and supporting healthcare providers, the company aims to increase diagnosis rates and help more men access the care they deserve.

The road ahead is filled with potential, and Keenova stands at the forefront, ensuring that the voices of patients are heard and that they have the support they need throughout their treatment journey.

Conclusion

Peyronie's disease may be common, but the conversation around it does not have to remain silent. Keenova's milestone of 100,000 patients treated with XIAFLEX is just the beginning of a broader commitment to transforming men's health and advocating for those affected by this condition.